Company Announcements

Director/PDMR Shareholding

Source: RNS
RNS Number : 8384U
Centrica PLC
30 March 2023
 

Centrica plc (the "Company")

30 March 2023

Notification of Transactions of Directors

Acquisition of Shares

On 29 March, Shares were acquired by an Executive Director as a result of the Free Share Award granted to all Centrica colleagues. The Shares were granted under the Share Incentive Plan and are subject to a three-year holding period.

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

Chris O'Shea

2

Reason for the notification

a)

Position/status

Executive Director

b)

Initial notification/Amendment

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Centrica plc

b)

LEI

E26EDV109X6EEPBKVH76

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial

instrument, type of instrument

 

Identification code

Ordinary Shares of 614/81 pence

 

 

GB00B033F229

b)

Nature of the transaction

Acquisition of Free Shares on behalf of a PDMR by Equiniti Share Plan Trustees Limited under the Company's Share Incentive Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£1.02783333

1,848

d)

Aggregated information

 

-      Total

 

 

 

£1,899.44

 

e)

Date of the transaction

29 March 2023

f)

Place of the transaction

Outside a trading venue

 

 

Centrica plc is listed on the London Stock Exchange (CNA)

Registered Office: Millstream, Maidenhead Road, Windsor, Berkshire SL4 5GD

Registered in England & Wales number: 3033654

Legal Entity Identifier number: E26EDV109X6EEPBKVH76

ISIN number: GB00B033F229

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHWPURUWUPWGQU